C-MER Medical Holdings (SEHK:3309) - Stock Price, News & Analysis

3309 Stock Overview

An investment holding company, provides ophthalmic services under the C-MER Dennis Lam brand name in Hong Kong and Mainland China. More details

3309 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 80.5% below our estimate of its fair value

Became profitable this year

Risk Analysis

3309 passed our risk checks.

C-MER Medical Holdings Limited Competitors

Chaoju Eye Care Holdings

SEHK:2219

HK$2.0b

Rici Healthcare Holdings

SEHK:1526

HK$1.9b

Honliv Healthcare Management Group

SEHK:9906

HK$1.2b

China Resources Medical Holdings

SEHK:1515

HK$5.0b

Price History & Performance

Summary of all time highs, changes and price drops for C-MER Medical Holdings
Historical stock prices
Current Share Price	HK$2.05
52 Week High	HK$3.75
52 Week Low	HK$1.81
Beta	0.62
11 Month Change	-12.77%
3 Month Change	-8.48%
1 Year Change	-45.33%
33 Year Change	-73.68%
5 Year Change	-58.42%
Change since IPO	-59.88%

Returns On Capital Signal Tricky Times Ahead For C-MER Medical Holdings (HKG:3309)

Nov 13

Is C-MER Medical Holdings (HKG:3309) A Risky Investment?

Oct 18

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

Sep 04

Recent updates

Returns On Capital Signal Tricky Times Ahead For C-MER Medical Holdings (HKG:3309)

Nov 13

Is C-MER Medical Holdings (HKG:3309) A Risky Investment?

Oct 18

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

Sep 04

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Jan 17

Shareholder Returns

	3309	HK Healthcare	HK Market
7D	0%	-0.6%	0.4%
1Y	-45.3%	-23.3%	12.0%

Return vs Industry: 3309 underperformed the Hong Kong Healthcare industry which returned -23.3% over the past year.

Return vs Market: 3309 underperformed the Hong Kong Market which returned 12% over the past year.

Price Volatility

Is 3309's price volatile compared to industry and market?
3309 volatility
3309 Average Weekly Movement	9.4%
Healthcare Industry Average Movement	8.2%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stable Share Price: 3309 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 3309's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	2,192	Dennis Lam	www.cmermedical.com

C-MER Medical Holdings Limited, an investment holding company, provides ophthalmic services under the C-MER Dennis Lam brand name in Hong Kong and Mainland China. The company operates through four segments: HK Medical Business, Sales of Medical Consumables, Mainland China Ophthalmic Business, and Mainland China Dental Business. It provides dental, oncology, medical aesthetics, and laboratory services; and engages in the sale of vision aid products, such as glasses and lens, and medical consumables.

C-MER Medical Holdings Limited Fundamentals Summary

How do C-MER Medical Holdings's earnings and revenue compare to its market cap?
3309 fundamental statistics
Market cap	HK$2.51b
Earnings (TTM)	HK$63.00m
Revenue (TTM)	HK$1.90b

39.9x

P/E Ratio

1.3x

P/S Ratio

Is 3309 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3309 income statement (TTM)
Revenue	HK$1.90b
Cost of Revenue	HK$1.29b
Gross Profit	HK$607.94m
Other Expenses	HK$544.93m
Earnings	HK$63.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.051
Gross Margin	32.06%
Net Profit Margin	3.32%
Debt/Equity Ratio	1.0%

How did 3309 perform over the long term?

See historical performance and comparison

3309 Stock Overview

Rewards

Risk Analysis

C-MER Medical Holdings Limited Competitors

SEHK:2219

HK$2.0b

SEHK:1526

HK$1.9b

SEHK:9906

HK$1.2b

SEHK:1515

HK$5.0b

Price History & Performance

Recent News & Updates

Returns On Capital Signal Tricky Times Ahead For C-MER Medical Holdings (HKG:3309)

Is C-MER Medical Holdings (HKG:3309) A Risky Investment?

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 18%

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

Recent updates

Returns On Capital Signal Tricky Times Ahead For C-MER Medical Holdings (HKG:3309)

Is C-MER Medical Holdings (HKG:3309) A Risky Investment?

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 18%

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 12% to HK$4.50

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

A Look At The Intrinsic Value Of C-MER Eye Care Holdings Limited (HKG:3309)

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Capital Allocation Trends At C-MER Eye Care Holdings (HKG:3309) Aren't Ideal

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

Is C-MER Eye Care Holdings (HKG:3309) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

Executive Director exercised options to buy HK$1.7m worth of stock.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Update: C-MER Eye Care Holdings (HKG:3309) Stock Gained 25% In The Last Year

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86